Rocket Lab pushes back first Neutron launch to 2027

Rocket Lab pushed Neutron’s maiden launch to 2027 after carbon-composite propellant-dome manufacturing defects delayed testing; CEO Peter Beck expects component testing to finish before the end of Q1 2027, with cryogenic and hydrostatic test campaigns now extending into that quarter. The schedule has slipped from an earlier Q4 2026 launch-pad delivery target, and shares fell from about $63 to near $53 in after-hours trading. Neutron is designed to carry up to 13,000 kg to Low Earth Orbit, but its launch timing remains uncertain.

Analysis

The key change is not simply a later revenue opportunity: repeated schedule resets raise the execution discount investors should apply to Neutron’s eventual economics. Composite quality problems that emerge during qualification can recur across components, so “problem solved” is not equivalent to demonstrated production repeatability. The next useful evidence is completed cryogenic/hydrostatic testing and a firm launch window—not management confidence alone.

Near term, the post-announcement selloff may already price in another delay; shorting into that gap has asymmetric squeeze risk if tests clear. Over the next 1–3 months, the catalyst is additional test disclosure and any change to the Q1 2027 testing expectation. Over 6–18 months, a successful first launch and repeatable cadence matter more than the first-flight date: without cadence, Neutron cannot credibly capture missions on the basis of theoretical capacity or reusability. Conversely, any Falcon 9 capacity withdrawal would create an opening only if Starship is not ready and Neutron is operational; that substitution thesis is conditional, not a current offset to execution risk.

Competitively, delays preserve incumbent launch providers’ bargaining power and could leave satellite operators with fewer credible alternatives if they had planned around Neutron. The bearish thesis is falsified by successful qualification, a credible revised schedule, and subsequent evidence of repeat launches. The bullish countercase is that a lower share price may overstate the damage if the defect is isolated and launch demand remains available—but neither claim is independently established here.

Key Decisions for Investors

• RKLB: avoid adding ahead of qualification evidence; for existing exposure, consider reducing position risk rather than automatically selling into the gap. Reassess after the company reports completion of cryo/hydrostatic testing and provides a specific launch window.
• Do not initiate an outright short solely on this delay. If seeking downside exposure, use a defined-risk put spread only after checking option-implied volatility and liquidity; the recent repricing increases the risk of paying too much for protection.
• Set an alert for any further slip beyond the stated Q1 2027 test-completion expectation, renewed component defects, or guidance changes that imply a slower path to repeat launches. Those would strengthen the execution-risk thesis; successful testing and a credible cadence plan would weaken it.
• Treat SpaceX/Falcon 9 displacement as a conditional medium-term opportunity, not a near-term hedge: monitor evidence on Falcon 9 retirement timing, Starship readiness, and launch-provider capacity before expressing a relative-value trade.